Coherus Biosciences: Quarterly Loss Exceeds Expectations – LOQTORZI Growth in Focus
This article was created with the help of artificial intelligence.
Key Takeaways
- Coherus Biosciences recorded a loss of $0.25 per share in Q1 2026, exceeding the consensus estimate of $0.18 per share.
- Compared to the prior-year quarter, the loss position improved from $0.35 per share in Q1 2025 to $0.25 per share in Q1 2026.
- The company expects increasing revenue growth for LOQTORZI for the second half of 2026, a drug for the treatment of nasopharyngeal carcinoma.
- LOQTORZI is aimed at a patient group with a rare tumor that occurs more frequently particularly in parts of Asia and North Africa.
- Coherus has increasingly evolved from a pure biosimilar provider to a company focused on innovative oncology therapies.
Coherus Biosciences Inc. (NASDAQ: CHRS) reported on May 11, 2026 for the first quarter 2026 a loss of $0.25 per share. This figure exceeded the Zacks consensus estimate, which had predicted a loss of $0.18 per share. Compared to the prior-year period, however, the loss decreased: In the first quarter 2025, the company had recorded a loss of $0.35 per share.
The oncology company based in Redwood City, California also missed analyst revenue expectations in the reporting quarter. The company did not provide specific revenue figures in the announcement from May 11, 2026.
LOQTORZI as a Growth Driver
In the course of the earnings call for the first quarter on May 11, 2026, Coherus Oncology outlined further business developments. The company expects increasing revenue growth for LOQTORZI for the remainder of 2026, a drug for the treatment of nasopharyngeal carcinoma – a cancer of the nasopharynx.
LOQTORZI is a central component of Coherus's oncology strategy. The drug is aimed at a patient group with a rare but difficult-to-treat tumor, which occurs more frequently particularly in parts of Asia and North Africa.
Pipeline Data in Preparation
In addition to the focus on LOQTORZI, Coherus is preparing several clinical data presentations from its oncology pipeline. These are to be published in the course of 2026. The company did not provide details on the drugs or studies in question in the earnings call on May 11, 2026.
The announced data could provide additional insights into the company's development strategy, which focuses on biosimilars – biotech-manufactured copycat products of biological drugs – and innovative oncology therapies.
Company Background
Coherus Biosciences is listed on Nasdaq under the ticker CHRS and develops and markets drugs in the field of oncology. In recent years, the company has increasingly evolved from a pure biosimilar provider toward innovative cancer therapies.
The financial reporting for the second quarter 2025 had been announced by Coherus for August 7, 2025 after market close on July 31, 2025. At that time, the company was still operating as Coherus Oncology, Inc.